Skip to Content

Join the 'Biliary Cirrhosis' group to help and get support from people like you.

Biliary Cirrhosis News

Ocaliva Approved for Rare Liver Disease

Posted 15 Jun 2016 by Drugs.com

TUESDAY, May 31, 2016 – Ocaliva (obeticholic acid) has been approved by the U.S. Food and Drug Administration to treat a rare chronic liver disease called primary biliary cholangitis (PBC). The disease causes the liver's small bile ducts to become inflamed, ultimately destroying the ducts and leading to cirrhosis, which is scarring of the liver. Over time, this leads to a potentially deadly loss of liver function, the agency said Tuesday in a news release. Ocaliva is designed to increase bile flow from the liver. The drug was evaluated in clinical studies involving 216 people, and the most commonly recorded side effects included itchy skin, fatigue, abdominal pain, throat pain, dizziness and constipation. Ocaliva should not be given to people whose bile ducts are completely blocked, the FDA warned. Clinical studies have not established an improvement in survival, progression to liver ... Read more

Related support groups: Biliary Cirrhosis, Obeticholic Acid, Ocaliva

FDA Grants Accelerated Approval to Ocaliva (obeticholic acid) for Primary Biliary Cholangitis

Posted 8 Jun 2016 by Drugs.com

NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) – Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic acid(UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Ocaliva is an agonist of the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways. "Intercept was founded on the belief that targeting FXR would benefit patients with liver ... Read more

Related support groups: Biliary Cirrhosis, Obeticholic Acid, Ocaliva

Substance Abuse, Suicide Killing More White, Middle-Aged Americans: Report

Posted 2 Nov 2015 by Drugs.com

MONDAY, Nov. 2, 2015 – A largely unnoticed "epidemic" is killing white, middle-aged Americans in growing numbers, a new analysis reveals. Princeton University researchers report that the overall death rate of white adults in midlife has risen sharply over the past 15 years, largely because of drug and alcohol overdoses, suicide, chronic liver disease and cirrhosis of the liver. The tally is on par with the nation's AIDS deaths, they added. "We sort of fell off our chairs when we saw that in the data, because that's just not what's happening elsewhere," said study author Anne Case, a professor of economics and public affairs. No other industrialized nation has experienced a similar deterioration in health during the timeframe studied – 1999 to 2013, the researchers said in background notes. Meanwhile, death rates of U.S. Hispanics and blacks continue to plummet. Results of the ... Read more

Related support groups: Oxycodone, Hydrocodone, OxyContin, Vicodin, Roxicodone, Cirrhosis, Liver Cirrhosis, Biliary Cirrhosis, Vicodin ES, Vicodin HP, Hysingla ER, OxyIR, Liver and Pancreatic Disease, Ethanol, Oxyfast, Zohydro ER, Hepatic Coma, Portal Hypertension, Dazidox, Roxicodone Intensol

Liver Damage From Hepatitis C More Widespread Than Thought

Posted 27 Aug 2015 by Drugs.com

THURSDAY, Aug. 27, 2015 – Severe liver damage may be four times more common among Americans with the liver infection hepatitis C than previously believed, a new study suggests. Analyzing nearly 9,800 patients with hepatitis C, researchers learned that using a biopsy alone to reveal liver cirrhosis – indicating scarring in the organ – is likely to seriously underestimate its prevalence. The recent emergence of medications that can cure hepatitis C, a "silent killer" that often goes undetected until advanced disease sets in years later, adds weight to the new findings, doctors said. "We thought it would be important to provide the health care community with some estimate as to the severity of liver disease among patients with hepatitis C because it's a question that comes up very frequently: Just how sick is this community?" said study author Dr. Stuart Gordon, director of hepatology ... Read more

Related support groups: Hepatitis C, Harvoni, Cirrhosis, Liver Cirrhosis, Biliary Cirrhosis

Study Links Coffee to Lower Risk for Rare Liver Disease

Posted 19 May 2013 by Drugs.com

SATURDAY, May 18 – Just a few extra cups of coffee each month might help prevent the development of an autoimmune liver disease known as primary sclerosing cholangitis (PSC), a new study suggests. Investigators from the Mayo Clinic in Rochester, Minn., found that drinking coffee was associated with a reduced risk of developing the disease, which can lead to cirrhosis of the liver, liver failure and biliary cancer. This association, however, does not prove a cause-and-effect relationship. "While rare, PSC has extremely detrimental effects," Dr. Craig Lammert, an instructor of medicine at the Mayo Clinic, said in a news release from the American Gastroenterological Association. "We are always looking for ways to mitigate risk, and our first-time finding points to a novel environmental effect that might also help us determine the cause of this and other devastating autoimmune diseases." ... Read more

Related support groups: Biliary Cirrhosis

Ask a Question

Further Information

Related Condition Support Groups

Liver Cirrhosis

Related Drug Support Groups

colchicine, ursodiol, azathioprine, Urso, Actigall, Urso Forte, Ocaliva, Urso DS, obeticholic acid